News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
The trial will be conducted across 10 sites in India
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively
First diagnostic centre to open in Mohali on August 31
Subscribe To Our Newsletter & Stay Updated
